The predictive value of 18F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy
暂无分享,去创建一个
M. Massaccesi | M. V. Mattoli | M. Calcagni | G. Mantini | V. Scolozzi | A. Castelluccia | Valentina Scolozzi
[1] K. Jöckel,et al. Standardized Uptake Decrease on [18F]-Fluorodeoxyglucose Positron Emission Tomography After Neoadjuvant Chemotherapy Is a Prognostic Classifier for Long-Term Outcome After Multimodality Treatment: Secondary Analysis of a Randomized Trial for Resectable Stage IIIA/B Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Nichol,et al. EGFR mutation status on brain metastases from non-small cell lung cancer. , 2016, Lung cancer.
[3] P. Allavena,et al. Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery , 2016, European Journal of Nuclear Medicine and Molecular Imaging.
[4] S. Demaria,et al. Can abscopal effects of local radiotherapy be predicted by modeling T cell trafficking? , 2016, Journal of Immunotherapy for Cancer.
[5] A. Khalil,et al. Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2′‐deoxy‐2′‐[18F] fluoro‐D‐glucose‐PET/CT scans to predict survival early during treatment of locally advanced non‐small cell lung cancer (NSCLC) , 2016, Journal of medical imaging and radiation oncology.
[6] P. Graziano,et al. Diagnostic Performance of (18)F-Fluorodeoxyglucose in 162 Small Pulmonary Nodules Incidentally Detected in Subjects Without a History of Malignancy. , 2016, The Annals of thoracic surgery.
[7] R. Fietkau,et al. Neoadjuvante Radiochemotherapie gefolgt von kurativer Resektion im fortgeschrittenen Stadium IIIA/IIIB eines nicht kleinzelligen Lungenkarzinoms: prognostische Faktoren und Ergebnisse , 2016, Zentralblatt für Chirurgie.
[8] G. Persson,et al. Early lesion-specific (18)F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[9] R. Rami-Porta,et al. Predicting the prognosis of lung cancer: the evolution of tumor, node and metastasis in the molecular age-challenges and opportunities. , 2015, Translational lung cancer research.
[10] A. Niemierko,et al. Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non-small cell lung cancer treated with radiotherapy for brain metastases. , 2015, Neuro-oncology.
[11] Eric J. W. Visser,et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.
[12] A. Sapino,et al. Primary systemic treatment and concomitant low dose radiotherapy for breast cancer: final results of a prospective phase II study. , 2014, Breast.
[13] P. Philip,et al. Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or limited metastatic pancreatic cancer. , 2014, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[14] E. Smit,et al. Trimodality therapy for stage IIIA non-small cell lung cancer: benchmarking multi-disciplinary team decision-making and function. , 2014, Lung cancer.
[15] Qiyong Ding,et al. PET/CT evaluation of response to chemotherapy in non-small cell lung cancer: PET response criteria in solid tumors (PERCIST) versus response evaluation criteria in solid tumors (RECIST). , 2014, Journal of thoracic disease.
[16] G. Maira,et al. Low-dose fractionated radiotherapy and concomitant chemotherapy for recurrent or progressive glioblastoma , 2014, Strahlentherapie und Onkologie.
[17] L. Indovina,et al. A prospective analysis of 18F-FDG PET/CT in patients with uveal melanoma: comparison between metabolic rate of glucose (MRglu) and standardized uptake value (SUV) and correlations with histopathological features , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[18] A. Alavi,et al. SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions , 2013, European Journal of Nuclear Medicine and Molecular Imaging.
[19] G. Scagliotti,et al. Early response to chemotherapy in patients with non-small-cell lung cancer assessed by [18F]-fluoro-deoxy-D-glucose positron emission tomography and computed tomography. , 2013, Clinical lung cancer.
[20] G. Michaud,et al. Treatment of stage III non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.
[21] Alessandro Brunelli,et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. , 2013, Chest.
[22] V. Valentini,et al. Low-dose radiotherapy as a chemo-potentiator of a chemotherapy regimen with pemetrexed for recurrent non-small-cell lung cancer: a prospective phase II study. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[23] L. Bonomo,et al. MRI evaluation of neoadjuvant low-dose fractionated radiotherapy with concurrent chemotherapy in patients with locally advanced breast cancer. , 2012, The British journal of radiology.
[24] L. Tanoue,et al. Lung cancer: epidemiology, etiology, and prevention. , 2011, Clinics in chest medicine.
[25] M. Mohiuddin,et al. Low-Dose Fractionated Radiation Potentiates the Effects of Cisplatin Independent of the Hyper-Radiation Sensitivity in Human Lung Cancer Cells , 2011, Molecular Cancer Therapeutics.
[26] K. Kerr,et al. Guidelines on the radical management of patients with lung cancer , 2010, Thorax.
[27] E. Felip,et al. Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] Jose Belderbos,et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] D. Lacombe,et al. EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] J. Welsh,et al. Pattern of failure following chemoradiation for locally advanced non-small cell lung cancer: potential role for stereotactic body radiotherapy. , 2010, Anticancer research.
[31] V. Valentini,et al. Low-dose hyperradiosensitivity: is there a place for future investigation in clinical settings? , 2010, International journal of radiation oncology, biology, physics.
[32] W. Curran,et al. Final Report of a Pilot Study of Carboplatin Plus Dose Dense Pemetrexed and Radiotherapy for Locally-advanced Non–small-cell Lung Carcinoma , 2009 .
[33] V. Rusch,et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial , 2009, The Lancet.
[34] R. Wahl,et al. From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.
[35] J. Crowley,et al. The revised TNM staging system for lung cancer. , 2009, Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia.
[36] B. Neyns,et al. Complete metabolic tumour response, assessed by 18-fluorodeoxyglucose positron emission tomography (18FDG-PET), after induction chemotherapy predicts a favourable outcome in patients with locally advanced non-small cell lung cancer (NSCLC). , 2008, Lung cancer.
[37] David W Townsend,et al. Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT , 2007, Journal of Nuclear Medicine.
[38] Matthias Reimold,et al. 18F-FDG PET for assessment of therapy response and preoperative re-evaluation after neoadjuvant radio-chemotherapy in stage III non-small cell lung cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[39] T. Naruke,et al. Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.
[40] Otto S Hoekstra,et al. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] T. Manabe,et al. [18F]FDG uptake and PCNA, Glut-1, and Hexokinase-II expressions in cancers and inflammatory lesions of the lung. , 2005, Neoplasia.
[42] T. Naruke,et al. Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT images. , 2004, Lung cancer.
[43] W. Regine,et al. Low-dose fractionated radiation as a chemopotentiator of neoadjuvant paclitaxel and carboplatin for locally advanced squamous cell carcinoma of the head and neck: results of a new treatment paradigm. , 2004, International journal of radiation oncology, biology, physics.
[44] Danny Rischin,et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] W. Regine,et al. Low-dose fractionated radiation potentiates the effects of Paclitaxel in wild-type and mutant p53 head and neck tumor cell lines. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[46] D. Wood,et al. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[47] F. Foppiano,et al. Induction chemotherapy followed by concurrent standard radiotherapy and daily low-dose cisplatin in locally advanced non-small-cell lung cancer , 1999, British Journal of Cancer.
[48] H. Tonami,et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[49] V J Lowe,et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. , 1995, The Annals of thoracic surgery.
[50] R L Wahl,et al. Fluorodeoxyglucose uptake in human cancer cell lines is increased by hypoxia. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[51] D. Naidich,et al. Diagnosis and Management of Lung Cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines , 2017 .
[52] R. Fietkau,et al. [Neoadjuvant Radiochemotherapy Followed by Curative Resection in Patients with Advanced Non-Small Cell Lung Cancer in Stage IIIA/IIIB: Prognostic Factors and Results]. , 2016, Zentralblatt fur Chirurgie.
[53] K. Hirata,et al. The Diagnosis and Treatment of Lung Cancer , 2014 .
[54] A. Jemal,et al. Global Cancer Statistics , 2011 .
[55] W. Oyen,et al. Biological correlates of FDG uptake in non-small cell lung cancer. , 2007, Lung cancer.
[56] T. Naruke,et al. Prognostic significance of [18F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma , 2006, Cancer.
[57] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[58] P C Goodman,et al. Evaluation of primary pulmonary carcinoid tumors using FDG PET. , 1998, AJR. American journal of roentgenology.